Papers
42
Total Citations
4,651
H-Index
25
About
Alessio Pigazzi is a pioneering surgical oncologist whose career has fundamentally shaped the adoption and validation of robotic-assisted colorectal surgery, with a particular focus on rectal cancer treatment. His research has systematically advanced the field from early feasibility studies to large-scale, multicenter clinical trials, establishing the safety, efficacy, and oncologic integrity of robotic total mesorectal excision (TME). Pigazzi's landmark 2017 randomized controlled trial comparing robotic-assisted to conventional laparoscopic rectal resection—now cited over 1,300 times—remains one of the most influential studies in minimally invasive colorectal surgery. His early 2006 work on robotic low anterior resection helped establish the procedural blueprint that surgeons worldwide would follow, while his 2010 multicentric studies confirmed sound oncologic outcomes, addressing critical concerns about cancer control. Beyond operative technique, Pigazzi pioneered the clinical application of indocyanine green fluorescence imaging to assess anastomotic perfusion, a now widely adopted innovation that demonstrably reduces devastating postoperative leak complications. With multiple papers exceeding 150–380 citations and contributions spanning national outcome analyses to prospective international trials, Pigazzi's cumulative impact has accelerated the global integration of robotic platforms into colorectal oncology, making him an essential reference point for any researcher or trainee entering this field.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10